Stemora Inc., based in Frederick, Md., is developing regenerative, stem cell–based approaches that target cartilage degeneration to halt and potentially reverse osteoarthritis. The company aims to deliver lasting structural restoration and functional recovery by addressing the root cause of the disease. In 2025 Stemora received funding from the Maryland Stem Cell Research Fund’s Commercialization Fund and in 2026 secured a $25,000 investment from TEDCO’s RBII program to continue R&D. Stemora’s public statements emphasize advancing research to stop and reverse cartilage degeneration and improve patients’ quality of life. The announcement did not disclose revenue, users, or other operating metrics.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026